Efficacy of Oseltamivir Phosphate Capsules Combined with Lianhua Qingwen Granules in the Treatment of Influenza A H1N1

ZHANG Linghui; YU Xuhong; ZHANG Chenxi; FANG Ningning; CHEN Ling; DENG Meiyu

doi:10.14009/j.issn.1672-2124.2021.08.016

您当前的位置：

首页 >

文章列表页 >

Efficacy of Oseltamivir Phosphate Capsules Combined with Lianhua Qingwen Granules in the Treatment of Influenza A H1N1

更新时间：2022-10-08

- Efficacy of Oseltamivir Phosphate Capsules Combined with Lianhua Qingwen Granules in the Treatment of Influenza A H1N1
- Vol. 21, Issue 8, Pages: 963-965(2021)
- 作者机构：
  
  1. 中国人民解放军第三〇五医院呼吸内科
  2. 中国人民解放军第三〇五医院药局
- 作者简介：
- 基金信息：
- DOI：10.14009/j.issn.1672-2124.2021.08.016
  CLC： R511.7
- Published：2021，
扫描看全文
ZHANG Linghui, YU Xuhong, ZHANG Chenxi, et al. Efficacy of Oseltamivir Phosphate Capsules Combined with Lianhua Qingwen Granules in the Treatment of Influenza A H1N1. [J]. 21(8):963-965(2021)
DOI：

ZHANG Linghui, YU Xuhong, ZHANG Chenxi, et al. Efficacy of Oseltamivir Phosphate Capsules Combined with Lianhua Qingwen Granules in the Treatment of Influenza A H1N1. [J]. 21(8):963-965(2021) DOI： 10.14009/j.issn.1672-2124.2021.08.016.

摘要

目的:探讨磷酸奥司他韦胶囊与连花清瘟颗粒联合治疗甲型H1N1流行性感冒的临床疗效。方法:选取2018年10月至2020年2月中国人民解放军第三〇五医院收治的甲型H1N1流行性感冒患者186例

按随机数字表法分为联合治疗组(采用磷酸奥司他韦胶囊和连花清瘟颗粒联合治疗

62例)、奥司他韦组(采用奥司他韦胶囊治疗

62例)以及连花清瘟组(采用连花清瘟颗粒治疗

62例)。比较三组患者的临床疗效、症状缓解时间、甲型流感病毒核酸转阴率和药品不良反应发生情况。结果:联合治疗组患者发热、全身症状、鼻部症状、咽痛和咳嗽/咳痰等症状缓解时间均较奥司他韦组、连花清瘟组更短

差异均有统计学意义(P<0.05)。联合治疗组患者的总有效率明显高于奥司他韦组、连花清瘟组

差异均有统计学意义(P<0.05);联合治疗组患者的甲型流感病毒核酸转阴率高于奥司他韦组

且明显高于连花清瘟组

联合治疗组与连花清瘟组的差异有统计学意义(P<0.05)。联合治疗组、奥司他韦组和连花清瘟组患者的不良反应发生率分别为6.5%(4/62)、6.5%(4/62)和4.8%(3/62)

三组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:采用磷酸奥司他韦胶囊与连花清瘟颗粒联合治疗甲型H1N1流行性感冒

能有效提高疗效

改善症状

提高甲型流感病毒核酸转阴率

且不良反应发生率低。

Abstract

OBJECTIVE: To probe into the clinical efficacy of oseltamivir phosphate capsules combined with Lianhua Qingwen granules in the treatment of influenza A H1 N1. METHODS: Totally 186 patients with influenza A H1 N1 admitted into the 305 Hospital of People’s Liberation Army from Oct. 2018 to Feb. 2020 were extracted to be divided into the combined treatment group（ Oseltamivir phosphate capsules combined with Lianhua Qingwen granules

n = 62）

oseltamivir group（ Oseltamivir phosphate capsules

n = 62） and Lianhua Qingwen group（ Lianhua Qingwen granules

n = 62） via random number table. The clinical efficacy

symptom relief time

negative rate of influenza A virus nucleic acid and adverse drug reactions were compared among three groups. RESULTS: The relief time of fever

systemic symptoms

nasal symptoms

sore throat and cough/expectotum in the combined treatment group was shorter than that in the oseltamivir group and Lianhua Qingwen group

with statistically significant difference（ P<0. 05）. The clinical efficacy in the combined treatment group were significantly higher than those in the oseltamivir group and Lianhua Qingwen group

with statistically significant difference（ P < 0. 05）. The negative rate of influenza A virus nucleic acid in the combined treatment group was higher than that in the oseltamivir group

and was significantly higher than that in the Lianhua Qingwen group（ with statistically significant difference

P < 0. 05）. The incidence of adverse drug reactions in the combined treatment group

oseltamivir group and Lianhua Qingwen group were respectively6. 5%（ 4/62）

6. 5%（ 4/62） and 4. 8%（ 3/62）

the incidence of adverse drug reactions in the combined treatment group was lower

and there was no significant difference among three groups（ P >0. 05）. CONCLUSIONS:Oseltamivir phosphate capsules combined with Lianhua Qingwen granules in the treatment of influenza A H1 N1 can effectively improve the efficacy and symptoms

and increase the negative rate of influenza A virus nucleic acid with lower incidence of adverse drug reactions.

关键词

磷酸奥司他韦连花清瘟颗粒甲型H1N1流行性感冒疗效

Keywords

Oseltamivir phosphateLianhua Qingwen granulesInfluenza A H1N1Efficacy

references

查看原文

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Retrospective Study of Efficacy and Safety of Lianhua Qingwen Granules Combined with Lopinavir/Ritonavir in the Treatment of COVID-19

Blood Trough Concentration Monitoring and Efficacy of Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection

Efficacy of Huaiqihuang Granules in the Adjuvant Treatment of Lupus Nephritis and Its Effects on Serum Ferritin

Prognosis and Safety of Programmed Death 1 Inhibitors in First-Line Treatment of Advanced Non-Small Cell Lung Cancer

Efficacy and Safety of Apatinib Mesylate Combined with Etoposide in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer

Related Author

夏一淼

王法财

沈炳香

聂松柳

LIU Yunning

LI Xiaofeng

TANG Jianhua

JIANG Aiwen

Related Institution

Lu’an People’s Hospital

Dept.of Microbiology, the First Affiliated Hospital of Hebei North University

Dept.of Pharmacy, the First Affiliated Hospital of Hebei North University

Dept.of Integrated Chinese and Western Medicine, Liyuan Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

Dept. of Oncology, Huangshan People’s Hospital

⁰